Quoin Pharmaceuticals and ER-Kim have expanded their exclusive distribution agreement for the former’s investigational therapy, QRX003, to treat Netherton Syndrome. QRX003 is being developed as a potential therapy to treat Netherton Syndrome, a rare, hereditary […]
The US Food and Drug Administration (FDA) has granted approval to the Janssen Pharmaceutical Companies of Johnson & Johnson’s first cell therapy Carvykti (ciltacabtagene autoleucel; cilta-cel) to treat relapsed or refractory multiple myeloma (RRMM) in […]
AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. They […]
Device innovations, connected delivery and regulatory guidance for advanced parenteral systems The global pre-filled syringes market was valued at $1139.6 million in 2020 and with the rapid growth of the industry, is expected to grow […]
Actinium Pharmaceuticals and Aveo Oncology have signed a research partnership for developing and analysing an ErbB3 (HER3)-targeting antibody radio-conjugate (ARC) for solid tumour treatment. Actinium’s Antibody Warhead Enabling (AWE) technology platform and its broad radiotherapy […]